Prof. Dr. med. Lukas Flatz
Oberarzt und Gruppenleiter
Oberarzt/Oberärztin
Dermatologie | Venerologie | Allergologie · Dept. IV
A novel proangiogenic B cell subset is increased in cancer and chronic inflammation
van de Veen W, Huntjens D, Wallimann A, Fonseca Guevara R, Spits H, Desislava I, Chang Y, Fassnacht C, Guenova E, Flatz L, Akdis C, van Splunter M, Stanić B, Herrmann M, Globinska A, Jansen K, Straumann A, Kubo T, Verschoor D, Wirz O, Castro-Giner F, Tan G, Rückert B, Ochsner U, Akdis M. A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. Sci Adv 2020; 6:eaaz3559.
13.05.2020A novel proangiogenic B cell subset is increased in cancer and chronic inflammation
13.05.2020Sci Adv 2020; 6:eaaz3559
van de Veen Willem, Huntjens Daan, Wallimann Alexandra, Fonseca Guevara Rodney J, Spits Hergen, Desislava Ignatova, Chang Yun-Tsan, Fassnacht Christina, Guenova Emmanuella, Flatz Lukas, Akdis Cezmi A, van Splunter Marloes, Stanić Barbara, Herrmann Marietta, Globinska Anna, Jansen Kirstin, Straumann Alex, Kubo Terufumi, Verschoor Daniëlle, Wirz Oliver F, Castro-Giner Francesc, Tan Ge, Rückert Beate, Ochsner Urs, Akdis Mübeccel
Palmoplantar Keratoderma with Leukokeratosis Anogenitalis Caused by KDSR Mutations
Huber M, Chiticariu E, Bachmann D, Flatz L, Hohl D. Palmoplantar Keratoderma with Leukokeratosis Anogenitalis Caused by KDSR Mutations. J Invest Dermatol 2020; 140:1662-1665.e1.
25.01.2020Palmoplantar Keratoderma with Leukokeratosis Anogenitalis Caused by KDSR Mutations
25.01.2020J Invest Dermatol 2020; 140:1662-1665.e1
Huber Marcel, Chiticariu Elena, Bachmann Daniel, Flatz Lukas, Hohl Daniel
Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
Gil Cruz C, Jahns R, Wyss M, Mooser C, Lambrecht B, Maeder M, Rickli H, Flatz L, Eriksson U, Geuking M, McCoy K, Boivin-Jahns V, Slack E, Arnoldini M, Pérez Shibayama C, De Martin A, Ronchi F, Van der Borght K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 2019; 366:881-886.
15.11.2019Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
15.11.2019Science 2019; 366:881-886
Gil Cruz Cristina, Jahns Roland, Wyss Madeleine, Mooser Catherine, Lambrecht Bart N, Maeder Micha, Rickli Hans, Flatz Lukas, Eriksson Urs, Geuking Markus B, McCoy Kathy D, Boivin-Jahns Valérie, Slack Emma M C, Arnoldini Markus, Pérez Shibayama Christian Ivan, De Martin Angelina, Ronchi Francesca, Van der Borght Katrien, Niederer Rebekka, Onder Lucas, Lütge Mechthild, Novkovic Mario, Nindl Veronika, Ramos Gustavo, Ludewig Burkhard
Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply
Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. JAMA Oncol 2019
03.10.2019Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply
03.10.2019JAMA Oncol 2019
Berner Fiamma, Bomze David, Flatz Lukas
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2019; 82:854-861.
23.08.2019BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
23.08.2019J Am Acad Dermatol 2019; 82:854-861
Hasan Ali Omar, Sadik Christian D, Zillikens Detlef, Schmidt Enno, Jochum Wolfram, Mani Bernhard, Cozzio Antonio, Braun Anne, Emtenani Shirin, Hammers Christoph, Abdou Marie-Therese, Diem Stefan, Fässler Mirjam, Berner Fiamma, Ring Sandra S, Bomze David, Flatz Lukas
Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. JAMA Oncol 2019
22.08.2019Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
22.08.2019JAMA Oncol 2019
Bomze David, Hasan Ali Omar, Bate Andrew, Flatz Lukas
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
01.07.2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
01.07.2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
01.04.2019Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
01.04.2019J Immunother 2019; 42:89-93
Diem Stefan, Risch Martin, Recher Mike, Risch Lorenz, Dummer Reinhard, Levesque Mitchell P, Mangana Joanna, Hillmann Dorothea, Niederer Rebekka, Berner Fiamma, Ali Omar Hasan, Bomze David, Fässler Mirjam, Flatz Lukas
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
20.02.2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
20.02.2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
14.02.2019A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
14.02.2019Clin Cancer Res 2019; 25:3026-3034
Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz
A Rare Case of Localized Argyria on the Face
Isak V, Beerli T, Cozzio A, Flatz L. A Rare Case of Localized Argyria on the Face. Case Rep Dermatol 2019; 11:23-27.
13.02.2019A Rare Case of Localized Argyria on the Face
13.02.2019Case Rep Dermatol 2019; 11:23-27
Isak Verena, Beerli Tobias, Cozzio Antonio, Flatz Lukas
Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation
Hartwig T, Schlapbach C, Conrad C, Flatz L, Dummer R, Navarini A, Cheng P, Yawalkar N, Schreiner B, Zwicky P, Becher B. Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Rep 2018; 25:3564-3572.e4.
26.12.2018Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation
26.12.2018Cell Rep 2018; 25:3564-3572.e4
Hartwig Tom, Schlapbach Christoph, Conrad Curdin, Flatz Lukas, Dummer Reinhard, Navarini Alexander, Cheng Phil, Yawalkar Nikhil, Schreiner Bettina, Zwicky Pascale, Becher Burkhard
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
07.12.2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
07.12.2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
08.11.2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
08.11.2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018
31.08.2018Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
31.08.2018Cancer Immunol Immunother 2018
Schmid Sabine, Jochum Wolfram, Klingbiel Dirk, Desbiolles Lotus, Leschka Sebastian, Flatz Lukas, Krapf Mirjam, Li Qiyu, Diem Stefan, Früh Martin
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncol Res Treat 2018; 41:391-394.
03.05.2018Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
03.05.2018Oncol Res Treat 2018; 41:391-394
Fischer Stefanie, Ali Omar H, Jochum Wolfram, Kluckert Jörg-Thomas, Flatz Lukas, Siano Marco
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
11.09.2017Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
11.09.2017Cancer Immunol Immunother 2017; 67:39-45
Diem Stefan, Hasan Ali Omar, Ackermann Christoph J, Bomze David, Koelzer Viktor H, Jochum Wolfram, Speiser Daniel E, Mertz Kirsten D, Flatz Lukas
Interferon-γ-Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever
Remy M, Merkler D, Kaufmann B, Hanisch U, Bestmann L, Rieger T, Doras C, Fallet B, Kreutzfeldt M, Xu L, Regen T, Flatz L, Sahin M, Pinschewer D. Interferon-γ-Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever. Cell Host Microbe 2017; 22:354-365.e5.
17.08.2017Interferon-γ-Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever
17.08.2017Cell Host Microbe 2017; 22:354-365.e5
Remy Melissa M, Merkler Doron, Kaufmann Beat A, Hanisch Uwe-Karsten, Bestmann Lukas, Rieger Toni, Doras Camille, Fallet Benedict, Kreutzfeldt Mario, Xu Lifen, Regen Tommy, Flatz Lukas, Sahin Mehmet, Pinschewer Daniel D
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
24.07.2017Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
24.07.2017Lung Cancer 2017; 111:176-181
Diem Stefan, Schmid Sabine, Krapf Mirjam, Flatz Lukas, Born Diana, Jochum Wolfram, Templeton Arnoud J, Früh Martin
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Kalkavan H, Rathbun J, Cannon P, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang P, Drexler I, von Laer D, Wollmann G, Sharma P, Kasper S, Helfrich I, Pandyra A, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle P, Lang K. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun 2017; 8:14447.
01.03.2017Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
01.03.2017Nat Commun 2017; 8:14447
Kalkavan Halime, Rathbun Jessica, Cannon Paula M, Scheu Stefanie, Bauer Jens, Chauhan Jagat, Häussinger Dieter, Willimsky Gerald, Löhning Max, Schadendorf Dirk, Brandau Sven, Schuler Martin, Lang Philipp A, Drexler Ingo, von Laer Dorothee, Wollmann Guido, Sharma Piyush, Kasper Stefan, Helfrich Iris, Pandyra Aleksandra A, Gassa Asmae, Virchow Isabel, Flatz Lukas, Brandenburg Tim, Namineni Sukumar, Heikenwalder Mathias, Höchst Bastian, Knolle Percy A, Lang Karl S